Cargando…
Circulating tumour markers can define patients with normal colons, benign polyps, and cancers
BACKGROUND: Early diagnosis represents the best opportunity for cure of colorectal cancer. Current screening programmes use faecal occult blood testing for screening, which has limited sensitivity and poor specificity. METHODS: In this study we looked at a series of previously described diagnostic m...
Autores principales: | Mead, R, Duku, M, Bhandari, P, Cree, I A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3142810/ https://www.ncbi.nlm.nih.gov/pubmed/21712823 http://dx.doi.org/10.1038/bjc.2011.230 |
Ejemplares similares
-
Isolation of tumour stem-like cells from benign tumours
por: Xu, Q, et al.
Publicado: (2009) -
Metabolic markers in blood can separate prostate cancer from benign prostatic hyperplasia
por: Giskeødegård, Guro F, et al.
Publicado: (2015) -
An immunohistochemical perspective of PPARβ and one of its putative targets PDK1 in normal ovaries, benign and malignant ovarian tumours
por: Ahmed, N, et al.
Publicado: (2008) -
Diagnostic value of CA19.9, circulating tumour DNA and circulating tumour cells in patients with solid pancreatic tumours
por: Sefrioui, David, et al.
Publicado: (2017) -
ADM3, TFF3 and LGALS3 are discriminative molecular markers in fine-needle aspiration biopsies of benign and malignant thyroid tumours
por: Karger, S, et al.
Publicado: (2012)